secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001104659-23-118751
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel restates financials for 2021-2023 due to $0.5M accounting error in contract deposits
--------------------------------------------------------------------------------

- Overstated operating loss by $293,845 in Q3 2021 and $255,450 in Q4 2021 from duplicate expense recognition.
- Net loss previously $18.9M in 2021 will decrease by $0.5M; total assets increase by $0.5M; cash unchanged.
- Management concludes disclosure controls ineffective; material weakness in internal controls over deposit-related invoices.
- Company plans to amend 2022 10-K and file restated quarterly reports for 2021-2023 periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923118751/0001104659-23-118751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923118751/tm2330847d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer